Parkinson's disease represents a $6-8 billion market today, projected to exceed $13 billion by the 2030s, driven by rising ...

As bispecifics, ADCs, protein degraders, and AI-designed mini-proteins move into the clinic, discovery teams face a new ...

A study carried out by the University of Bonn and the University Hospital Bonn throws light on how an important receptor can ...

In a little over ten years, organoid models—miniature, lab-grown clusters of cells that imitate real organs—have transformed how we study human development and disease while accelerating drug ...

The coming era of biosecurity will demand a broader and more adaptive approach as AI, powerful biological engineering ...

Learn how Ignota Labs is addressing drug toxicity challenges through AI, aiming to revive effective yet shelved drugs.

A new University of California San Diego School of Medicine study offers a unified biological model to explain how genetic predispositions and environmental exposures converge to cause autism spectrum ...

Smart multi-target drugs are redefining how we treat complex diseases by combining AI-driven discovery with mechanistic insights to deliver more effective, resilient, and personalized therapies.

EMA grants Orphan Drug Designation to Kedrion Biopharma’s plasma-derived treatment for aceruloplasminemia, a rare genetic disorder of iron metabolism: Castelvecchio Pascoli, Ita ...

ToxPredictor accurately predicts drug induced liver injury (DILI) to offer a valuable “go/no-go” tool in clinical decision making.

For drug discovery and biomarker development, peptide-level validation strengthens confidence that selected targets represent ...